South San Francisco, CA - February 13, 2007 - FibroGen, Inc. today announced the appointment of Sarah A. O'Dowd as Vice President & General Counsel. Ms. O'Dowd brings to FibroGen more than twenty-five years of experience with Heller Ehrman LLP, a leading U.S.-based law firm, where she was a shareholder of the firm and a member of its senior management. She joins FibroGen's senior management team, and will also direct the company's worldwide legal affairs.

At Heller Ehrman, Ms. O'Dowd specialized in finance, securities and corporate governance. In addition to serving as principal outside counsel to a variety of prominent Silicon Valley companies, she held a number of management and leadership positions at the firm. Most recently she chaired Heller Ehrman's corporate governance practice. Over the past 15 years, she held a number of other positions including head of the firm's corporate practice and member of the firm's three-person Executive Committee. She also had roles as managing shareholder for the Silicon Valley and San Diego offices of Heller Ehrman. She served on the firm's Policy Committee for over a decade. She has extensive experience with financing transactions, mergers and acquisitions, joint ventures, strategic arrangements and Sarbanes-Oxley.

"Sarah joins FibroGen at a critical time as we continue to grow our organization and advance products through clinical development and toward commercialization," said Thomas B. Neff, Chief Executive Officer of FibroGen. "Her expertise and counsel will be particularly valuable as we continue to expand our role as a leading provider of therapeutics answering unmet medical needs."

Ms. O'Dowd holds a J.D. from Stanford Law School, an M.A. in Communications from Stanford University, and graduated summa cum laude with an A.B. in mathematics from Immaculata College. She is a member of the State Bar of California.

About FibroGen

FibroGen, Inc. is a biotechnology-based drug discovery company using its expertise in the fields of tissue fibrosis, connective tissue growth factor (CTGF), and hypoxia-inducible factor (HIF) biology to discover, develop, and commercialize novel therapeutics for fibrotic disorders, diabetic complications, anemia, conditions associated with tissue damage or injury, cancer, and other areas of unmet medical need. FibroGen also develops and produces recombinant human collagens and gelatins using unique production technology that provides the basis for FibroGen's proprietary cosmetic dermal filler and biomaterials supply business.

For more information about FibroGen, Inc., please visit www.fibrogen.com.

Contact:
Laura Hansen 650-866-7828 or lhansen@fibrogen.com